The Partnership launches Electronic Synoptic Pathology Reporting Initiative (ESPRI) to advance pan-Canadian standardized cancer pathology reporting
Options
Email
Print
Twitter Facebook MySpace
Delicous Stumble Digg
More...
July 18th, 2012

The Partnership launches Electronic Synoptic Pathology Reporting Initiative (ESPRI) to advance pan-Canadian standardized cancer pathology reporting

ESPRI aims to further the adoption and implementation of electronic synoptic pathology reporting in Canada to drive practice improvements across the cancer care continuum.   Through this Initiative, advancements will be made to the depth and consistency of pathology information collected leveraging the CAP cancer protocols (the national content standard for cancer pathology reporting), ensuring that the information necessary to provide timely, top-quality care is available to inform treatment decisions. 

In close collaboration with provincial partners, these investments may include upgrades to infrastructure, support for systems integration to enable data transfer, as well as education and support to promote adoption of standards. 

In order to achieve these targets and manage scope, a two-phased approach will be leveraged.  Phase one will involve provincial planning, while phase two will involve provincial implementation(s) of electronic synoptic pathology solutions. The start of each phase will be preceded by the issuance of an RFP by the Partnership, to which interested parties can respond.  

Current Status: Planning Phase – SV2012-O1P Adjudication 

For further details, please refer to the following documents:

At a high level, ESPRI will focus on:

I. Supporting the adoption and advancing the implementation of electronic synoptic pathology resection reporting in discrete field formats for Breast, Colorectal, Lung, Prostate and Endometrial cancers

II. Maintaining and promoting the adoption of pan-Canadian mechanisms to support the necessary standards

III. Advancing the use of standardized data by generating performance indicators to measure completeness and compliance, as well as additional derivable clinical indicators

ESPRI Provincial Initiative In-Scope:

I. Planning and implementation of electronic synoptic pathology resection reporting in discrete field formats (level 5-6) at a recommended capture rate of 90% for all Breast, Colorectal, Lung, Prostate and Endometrial cancers utilizing the mandatory elements of the College of American Pathologists’ (CAP) Cancer protocols

II. Enabling the electronic generation of indicators by provincial partners to measure:

       a)      Compliance to the CAP Cancer protocols (% of reports and institutions leveraging discrete field formats)

       b)      Completeness (% of mandatory fields complete)

       c)      Potentially derivable clinical indicators

III. Integration of electronic synoptic pathology data into existing e-Health infrastructure, including:

       a)      Provincial Cancer Registry

       b)      Provincial Lab System (where applicable)

       c)      Provincial EHR (where applicable)

       d)      Institutional HIS

Provincial Initiative Out-of-Scope

The Partnership will not fund the following components which either do not support the goals of the Initiative or have been funded through other initiatives:

I.  Implementation of systems which do not support the CAP eCC XML or equivalent

II. Implementation of systems which do not support CHI’s electronic synoptic pathology Canadian Approved Standards

III. Voice recognition/dictation based systems

IV.  E-Path related products

V.  Digital and tele-pathology image scanning

VI.  Vendor Certification (i.e. working directly with vendors to provide certification offerings)

As stated, in order to achieve these targets and manage scope, a two-phased approach will be leveraged.  Phase one will involve provincial planning, while phase two will involve provincial implementation(s) of electronic synoptic pathology solutions. Timelines for the Initiative and the ESPRI RFP #1 are as follows:

The ESPRI RFP#1 timeline for posting, response and subsequent planning phase is as follows: 

For more information please contact: pathology@partnershipagainstcancer.ca